Suplementacija fruktanima tipa inulina poboljšava kontrolu glikemije za populaciju sa predijabetesom i dijabetesom tipa 2: rezultat je sistematskog pregleda procijenjenog GRADE i meta-analize doze-odgovora u 33 randomizirana kontrolirana ispitivanja.
Journal of translational medicine
Sažetak istraživanja
Pozadina Trenutno, mnoga klinička ispitivanja su pokazala da je suplementacija fruktanima tipa inulina (ITF) povezana sa kontrolom glikemije; ipak, rezultati su neuvjerljivi.
Cilj ove meta-analize randomiziranih kontroliranih studija bio je procijeniti efekte suplementacije ITF-om na kontrolu glikemije.
Metode PubMed, EMBASE i Cochrane biblioteka su pretražene za članke koji ispunjavaju uslove do 6. marta 2019. Za analizu objedinjenih rezultata korišten je model slučajnih efekata, a za procjenu kvaliteta dokaza primijenjen je sistem ocjenjivanja preporuka, razvoja i evaluacije (GRADE). Model doza-odgovor korišten je za preporuku dnevne doze i trajanja suplementacije ITF-om.
Rezultati Uključena su 33 ispitivanja koja su uključivala 1346 učesnika. Sve u svemu, ITF suplementacija bi mogla značajno smanjiti koncentraciju glukoze u krvi natašte (FBG), glikoziliranog hemoglobina (HbA1c), inzulina natašte (FINS) i modela homeostaze za procjenu inzulinske rezistencije (HOMA-IR). U populaciji predijabetesa i dijabetesa tipa 2 (T2DM), značajnije smanjenje FBG [ponderisana srednja razlika (WMD): - 0,60 mmol/l; 95% CI - 0,71, - 0,48 mmol/l; visoka stopa], HbA1c (WMD: - 0,58%; 95% CI - 0,83, - 0,32%; visoka stopa), FINS (WMD: - 1,75 µU/ml; 95% CI - 2,87, - 0,63 µU/ml; niska stopa; -WHO- 9%; i MD09. CI - 1,10, - 0,28 niska stopa) i preporučena je suplementacija ITF-om dnevnom dozom od 10 g u trajanju od 6 sedmica i duže. Štaviše, analize podgrupa sugerišu da su na efekte kontrole glikemije značajno uticali pol ispitanika i vrsta i način uzimanja ITF-a.
Zaključci Naše analize su potvrdile da su ova četiri glavna glikemijska indikatora značajno smanjena suplementacijom ITF-a, posebno u populaciji sa predijabetesom i T2DM. Dokazi potvrđuju da razumna primjena ITF suplemenata može imati potencijalnu kliničku vrijednost kao pomoćna terapija za liječenje predijabetesa i T2DM. Registracija suđenja Suđenje je registrovano u PROSPERO-u kao CRD42018115875 23. novembra 2018.
Prikaži originalni naslov i sažetak na engleskom
Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials.
Background Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic control.
Methods PubMed, EMBASE and the Cochrane Library were searched for eligible articles up to March 6, 2019. A random-effects model was used to analyze the pooled results, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to assess the quality of evidence. The dose-response model was used to recommend the daily dose and duration for ITF supplementation.
Results Thirty-three trials involving 1346 participants were included. Overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR). In the prediabetes and type 2 diabetes (T2DM) population, a more significant reduction in FBG [weighted mean difference (WMD): - 0.60 mmol/l; 95% CI - 0.71, - 0.48 mmol/l; high rate], HbA1c (WMD: - 0.58%; 95% CI - 0.83, - 0.32%; high rate), FINS (WMD: - 1.75 µU/ml; 95% CI - 2.87, - 0.63 µU/ml; low rate), and HOMA-IR (WMD: - 0.69; 95% CI - 1.10, - 0.28; low rate) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended. Moreover, subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF.
Conclusions Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population. Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management. Trial registration The trial was registered at PROSPERO as CRD42018115875 on November 23, 2018.
Izvorni podaci
- DOI
- 10.1186/s12967-019-02159-0
- PMID
- 31805963
- PMCID
- PMC6896694
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom